. 2009 Dec 7;31(1):27–34. doi: 10.1038/aps.2009.170

Table 1. Effects of ZK₁₄ on serum ALT, AST, HA, PCIII, and NO level in hepatic fibrosis rats induced by CCl₄. Mean±SD. ^bP<0.05, ^cP<0.01 vs normal. ^eP<0.05, ^fP<0.01 vs model.

Groups	Dose (mg/kg)	n	ALT (U/L)	AST (U/L)	HA (ng/mL)	PCIII (ng/mL)	NO (μg/L)
Normal	/	6	22.73±3.5	113.35±11.35	248.19±37.53	7.85±2.15	50.69±15.37
Model	/	8	50.12±12.56^b	222.83±25.36^b	1017.45±52.84^c	35.36±9.70^c	42.34±14.21
ZK₁₄	20	10	35.74±7.05^e	145.19±34.77^e	422.27±56.23^f	20.93±6.73^f	154.84±29.49^c
ZK₁₄	10	10	47.16±25.72	208.41±32.45	957.62±52.01	39.88±8.45	96.67±20.45^b
DDB	5	10	27.47±30.37^e	136.79±30.43^e	967.46±66.32	32.72±8.78	46.88±12.20

Table 1. Effects of ZK14 on serum ALT, AST, HA, PCIII, and NO level in hepatic fibrosis rats induced by CCl4. Mean±SD. bP<0.05, cP<0.01 vs normal. eP<0.05, fP<0.01 vs model.